High dose albumin treatment for patients with refractory ascites

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of high-dose albumin infusions in patients suffering from refractory ascites due to advanced liver cirrhosis. The study aims to determine whether regular albumin administration can reduce the need for paracentesis and prevent complications associated with fluid accumulation in the abdomen. Patients will be randomly assigned to receive either the albumin treatment or standard care, with various health outcomes measured over a twelve-month period, including mortality rates and quality of life. The trial is designed to provide insights into the effectiveness of albumin in managing this challenging condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 years.
2. patients diagnosed with liver cirrhosis.
3. Refractory ascites which is defined as ascites failing to resolve after maximum tolerable dose of diuretics, and usually require frequent paracentesis.

Exclusion Criteria:

1. Patients \< 18y
2. patients with no history of liver cirrhosis
3. patients with refractory ascites but have transjagular intrahepatic portosystemic shunts (TIPS) with previous 3 months
4. Patients with ascites due to other causes, including cardiac, malignant

Where it's running

• Baylor St' Lukes Medical center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Prasun Jalal, MD — Baylor College of Medicine
• Study coordinator: Prasun Jalal, MD
• Email: jalal@bcm.edu
• Phone: 8323551424

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Intraperitoneal SK-NK cell infusion for advanced ovarian cancer with massive ascites

  This will try giving highly activated donor NK cells directly into the abdomen once weekly for four weeks to see if it helps people with advanced ovarian cancer who have large-volume malignant ascites and no standard treatment options.

  Recruiting Phase 1/2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07435701

• VIATORR TIPS 6–10 mm: Real-world use in cirrhosis with portal hypertension

  A real-world registry is seeing how the GORE VIATORR TIPS Endoprosthesis with Controlled Expansion 6-10 mm works over 2 years in adults with cirrhosis and portal hypertension.

  Recruiting at 5 sites W.L.Gore & Associates · Atlanta, Georgia and 4 other locations · NCT07390344

• Intravenous contrast-enhanced ultrasound for diagnosing children's abdominal problems in China

  This project will try intravenous contrast-enhanced ultrasound in children (29 days–18 years) with abdominal tumors, injuries, or unexplained fluid to see if it gives clearer diagnoses.

  Recruiting The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07113808

• Evaluating drug sensitivity in organoids from breast cancer patients with fluid buildup

  This study is testing how well standard chemotherapy drugs work on lab-grown samples from breast cancer patients with fluid buildup to help personalize their treatment.

  Recruiting at 3 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 2 other locations · NCT06658080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.